Investing.com - VBI Vaccines (NASDAQ: VBIV) reported first quarter EPS of $-0.080, worse than the analyst estimate of $-0.070. Revenue for the quarter came in at $3.4M versus the consensus estimate of $1.98M.
VBI Vaccines's stock price closed at $0.350. It is down -31.020% in the last 3 months and down -71.810% in the last 12 months.
VBI Vaccines saw positive EPS revisions and negative EPS revisions in the last 90 days. See VBI Vaccines's stock price’s past reactions to earnings here.
According to InvestingPro, VBI Vaccines's Financial Health score is "weak performance".
Check out VBI Vaccines's recent earnings performance, and VBI Vaccines's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar